Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUS-CPN with or without Bupivacaine for Pancreatic Cancer Pain
NCT02682082Terminated
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- May 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bupivacaine in pancreatic cancer (PC), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Pain Score at 120 days. Started May 2016; status: terminated.
02
Drugs
bupivacaine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02682082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682082.